We are looking towards Bristol-Myers Squibb initiating a Stage 1 medical trial shortly. The swiftness of development of BMS-PCSK9Rx exemplifies the effectiveness of our technology and our capability to quickly advance from the discovery of a gene to a medication in the clinic,’ said Stanley T. Crooke, M.D., Ph.D., Chief and Chairman Executive Officer of Isis. ‘Targeting PCSK9 presents a unique method of lowering LDL cholesterol, which really is a key component in preventing and handling cardiovascular disease. We continue to progress and mature the breadth and depth of our pipeline and the therapeutic possibilities that we can take benefit of with our technology.’ Related StoriesStopping cholesterol medicines before surgery may boost risk of loss of life during recoveryPresence of tophi in people with gout can increase threat of developing cardiovascular diseaseFour microRNAs may actually play critical roles in managing cholesterol, triglyceride metabolismBMS-PCSK9Rx is an antisense drug that targets proprotein convertase subtilisin kexin 9, or PCSK9.Platelet counts were also increased by 59 to 64 percent in two syngeneic mouse types of ovarian cancer . To assess generalizability, we also quantified platelets in mouse models of breast tumor , uterine tumor , and pancreatic tumor . Platelet counts had been considerably increased in the types of uterine and pancreatic tumor but not in the breast-cancers model . Platelet counts began to rise whenever a tumor was detected by bioluminescence imaging and elevated in parallel with grossly measurable disease . An Underlying Mechanism of Paraneoplastic Thrombocytosis To test the hypothesis that factors produced by cancers cells or host cells stimulate megakaryopoiesis and paraneoplastic thrombocytosis, we 1st enumerated megakaryocytes in the bone marrow and spleens from tumor-bearing mice.